Plus Therapeutics, Inc. (PSTV)
Plus Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Austin, TX, US. The stock last traded at $3.87, down 3.25% on the session, giving a market capitalisation of $9.4M. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -620.7%. Its beta of 1.40 implies it has historically moved more than the broad market.
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Plus Therapeutics, Inc. is most often compared with the following Healthcare names: